# Tempest Therapeutics, Inc.: Form 10-Q for the period ended Jun 30, 2015

- Company: [Tempest Therapeutics, Inc.](/companies/tpst.md) (CIK 1544227)
- Form: 10-Q
- Filed: 2015-08-10
- Accepted by EDGAR: Aug 10, 2015, 16:09 ET
- Period: 2015-06-30
- Accession: 0001628280-15-006379
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1544227/000162828015006379/ovas-20150630x10q.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1544227/000162828015006379/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2015-06-30.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 3 months, 2015-04-01 to 2015-06-30 | $30.0k | us-gaap:Revenues |
| Revenue | 6 months, 2015-01-01 to 2015-06-30 | $45.0k | us-gaap:Revenues |
| Cost of revenue | 3 months, 2015-04-01 to 2015-06-30 | $116.0k | us-gaap:CostOfRevenue |
| Cost of revenue | 6 months, 2015-01-01 to 2015-06-30 | $151.0k | us-gaap:CostOfRevenue |
| Research and development | 3 months, 2015-04-01 to 2015-06-30 | $4.0m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 6 months, 2015-01-01 to 2015-06-30 | $9.8m | us-gaap:ResearchAndDevelopmentExpense |
| Selling, general and administrative | 3 months, 2015-04-01 to 2015-06-30 | $13.1m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Selling, general and administrative | 6 months, 2015-01-01 to 2015-06-30 | $24.1m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months, 2015-04-01 to 2015-06-30 | −$17.2m | us-gaap:OperatingIncomeLoss |
| Operating income | 6 months, 2015-01-01 to 2015-06-30 | −$34.0m | us-gaap:OperatingIncomeLoss |
| Net income | 3 months, 2015-04-01 to 2015-06-30 | −$17.5m | us-gaap:NetIncomeLoss |
| Net income | 6 months, 2015-01-01 to 2015-06-30 | −$34.7m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months, 2015-04-01 to 2015-06-30 | −$0.64 | us-gaap:EarningsPerShareBasicAndDiluted |
| Diluted EPS | 6 months, 2015-01-01 to 2015-06-30 | −$1.29 | us-gaap:EarningsPerShareBasicAndDiluted |
| Operating cash flow | 6 months, 2015-01-01 to 2015-06-30 | −$26.4m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 6 months, 2015-01-01 to 2015-06-30 | $1.1m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | at 2015-06-30 | $70.2m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2015-06-30 | $159.2m | us-gaap:AssetsCurrent |
| Total assets | at 2015-06-30 | $164.5m | us-gaap:Assets |
| Current liabilities | at 2015-06-30 | $7.6m | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2015-06-30 | $7.7m | us-gaap:Liabilities |
| Shareholders' equity | at 2015-06-30 | $156.7m | us-gaap:StockholdersEquity |

## Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. https://www.sec.gov/Archives/edgar/data/1544227/000162828015006379/ovas-20150630x10q.htm

Filed Aug 10, 2015.
Source: SEC EDGAR, the filing index for accession 0001628280-15-006379. Last ingested by Listed: Nov 15, 2026, 00:20 ET. No prices; not investment advice.
